TITLE

NexMed reports net loss for second quarter

PUB. DATE
October 1999
SOURCE
Biotech Financial Reports;Oct99, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on Robbinsville, New Jersey-based NexMed Inc.'s announcement of its revenue for the quarter ended June 30, 1999. Total net loss; Total sale from its joint venture operations in China; Information on the company.
ACCESSION #
2289135

 

Related Articles

  • NexMed Completes Study on Topical Impotence Treatment.  // Worldwide Biotech;Oct99, Vol. 11 Issue 10, p1 

    Reports on the announcement of NexMed Inc. on the evaluation of its proprietary alprostadil cream for treating male erectile dysfunction (MED) in a multiple-use clinical study in China that involved patients afflicted with MED. Results of the clinical study; Comments from Doctor Y. Joseph Mo,...

  • NexMed garners Japanese patent.  // Medical Device Daily;6/28/2010, Vol. 14 Issue 123, p7 

    The article reports on the decision of Japan's Patent Office to approve NexMed's patent "Prostaglandin Composition for the Treatment of Male Erectile Dysfunction."

  • NEXMED DEVELOPING TREATMENT FOR PREMATURE EJACULATION.  // Biotech Business;Sep2003, Vol. 16 Issue 9, p4 

    Reports the progress in the topical treatment for premature ejaculation development project of NexMed Inc., a developer of innovative transdermal treatments based on its NexACT proprietary drug delivery technology.

  • INVEST NEW JERSEY. McKnight, Marshall // Business News New Jersey;12/05/2000, Vol. 13 Issue 49, p16 

    Focuses on the increased stock prices of New Jersey-based NexMed Inc. Growth of stock value following the completion of the Phase III of the company's Befar erectile dysfunction cream.

  • Bio-Quant Successor Attracts $2.3M Investment. Chambers, Heather // San Diego Business Journal;2/15/2010, Vol. 31 Issue 7, p5 

    The article reports on the 2.3 million U.S. dollars promissory notes raised by NexMed Inc. from two investors in connection to its acquisition of San Diego-based Bio-Quant Inc.

  • Financings Roundup.  // BioWorld Today;5/15/2008, Vol. 19 Issue 95, p3 

    The article reports on a binding commitment entered by NexMed Inc. of East Windsor, New Jersey with one of its largest shareholders for a line of credit. The company intends to use the money to bridge the anticipated payments from partner Novartis AG, which licensed rights to NM100060 of NexMed....

  • NexMed Shares Fall Hard as Novartis Nixes NDA. Hollingsworth, Catherine // BioWorld Today;8/28/2008, Vol. 19 Issue 168, p1 

    The article reports on a decline in the value of NexMed's shares by 81.6% after its partner, Novartis AG, decided not to file for a new drug application for a topical nail fungus product that uses NexMed's drug delivery technology. Such decision by Novartis was attributed to a negative Phase III...

  • FINANCINGS ROUNDUP.  // BioWorld Today;3/18/2010, Vol. 21 Issue 52, p8 

    This section offers news briefs on biotechnological companies. Biomoda Inc. has partnered with a syndicate of institutional investors for a placement of up to 2 million U.S. dollars with LifeTech Capital acting as the exclusive placement agent. NexMed Inc. produced 1.4 million U.S. dollars after...

  • New money breathes life into NexMed. Goldblatt // Business News New Jersey;10/11/99, Vol. 12 Issue 37, p10 

    Reports on Robbinsville, New Jersey-based NexMed's private placement of securities in October 1999. Amount raised from the placement; Background information about the company's lead product, Alprox-TD for male sexual dysfunction; Profile on Chief Executive Officer Y. Joseph Mo; Key to the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics